• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioAge Labs, Inc. - Common Stock (NQ:BIOA)

16.15 -0.10 (-0.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about BioAge Labs, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025
March 24, 2026
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 19, 2026
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
January 21, 2026
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Announces Proposed Public Offering
January 20, 2026
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
January 20, 2026
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
January 12, 2026
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
December 04, 2025
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs to Present at Jefferies Global Healthcare Conference in London
November 07, 2025
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 06, 2025
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BIOAGE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
October 02, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
BioAge Labs to Present at Upcoming Investor Conferences
August 20, 2025
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
August 15, 2025
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 06, 2025
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
July 02, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
June 21, 2025
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank
June 17, 2025
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates
June 03, 2025
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic
May 29, 2025
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BioAge Labs to Present at Upcoming Investor Conferences
May 27, 2025
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
May 21, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates
May 06, 2025
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
Notice to Long-Term Shareholders of BioAge Labs, Inc. (NASDAQ: BIOA); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Integra LifeSciences Holdings Corporation (NASDAQ: IART); and Monolithic Power Systems, Inc. (NASDAQ: MPWR): Grabar Law Office Investigates
April 24, 2025
From Grabar Law Office
Via GlobeNewswire
News headline image
Notice to Long-Term Shareholders of BioAge Labs, Inc. (NASDAQ: BIOA); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Integra Lifesciences Holdings Corporation (NASDAQ: IART); and Monolithic Power Systems, Inc. (NASDAQ: MPWR): Grabar Law Office Investigates
April 22, 2025
From Grabar Law Office
Via GlobeNewswire
News headline image
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of BioAge Labs, Inc. (NASDAQ: BIOA); NAPCO Security Technologies, Inc. (NASDAQ: NSSC); Treace Medical Concepts, Inc. (NASDAQ: TMCI); and Virtu Financial Inc. (NASDAQ: VIRT)
April 17, 2025
From Grabar Law Office
Via GlobeNewswire
News headline image
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
March 20, 2025
From BioAge Labs, Inc.
Via GlobeNewswire
News headline image
BIOA DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages BioAge Labs, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action – BIOA
March 10, 2025
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securities Fraud Lawsuit with the Schall Law Firm
March 10, 2025
From The Schall Law Firm
Via Business Wire
News headline image
Final BIOA Deadline Reminder: March 10, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer &amp; Check, LLP
March 10, 2025
RADNOR, PA - March 10, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against BioAge... 
Via TheNewswire.com
Topics Initial Public Offering Lawsuit
News headline image
Final BIOA Deadline Reminder: March 10, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
March 10, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Initial Public Offering Lawsuit
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap